The U.S. is inching closer to approving its first biosimilar.
"We are pleased with the ODAC's recommendation to approve our biosimilar filgrastim and we look forward to continuing to work with FDA as it completes its review of our filing," said Mark McCamish, M.D., Ph.D., Head of Global Biopharmaceutical & Oncology Injectables Development at Sandoz, in a news release.
If approved in the U.S., Sandoz proposes to market the biosimilar under the name ZARXIO.
The drug is used during chemotherapy to fight off infections.
Sandoz is a Novartis company.